The mutation status of KIT and PDGFRA [4,5], together with the tumor location, tumor size, and mitotic count [6], are prognostic factors and aid in clinical decisions on whether to offer medical oncological treatment to the patients before and after surgery [7,8]. Here, KIT is linked to neoplasm.